WilmerHale Advises Cue Health in IPO

WilmerHale Advises Cue Health in IPO

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Critical industry insight and formidable strength across key practices.

On September 23, 2021, Cue Health (Nasdaq: HLTH), a health technology company, announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a public offering price of $16.00 per share, for gross proceeds of $200.00 million, before deducting underwriting discounts and commissions and other offering expenses payable by Cue Health. 

Cue Health’s common stock began trading on the Nasdaq Global Select Market on September 24, 2021 and the offering is expected to close on September 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Cue Health has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

The WilmerHale team advising Cue Health is led by Todd Rumberger and Glenn Pollner and includes Molly Fox, Craig Hilts, Dimitry Lensky, Andrea Sorrentino, Jahnvi Desai, Amanda Navarro and Benn Waters, with assistance from Fred Adam, Ciara Baker, Kimberly Wethly, Rebecca Chang, Benjamin Kelsey, Gavin Tullis and Heidi Treiber. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel